Literature DB >> 2878667

Effect of five structurally diverse H2-receptor antagonists on drug metabolism.

M Pasanen, P Arvela, O Pelkonen, E Sotaniemi, U Klotz.   

Abstract

Some H2-receptor antagonists can interact with the biotransformation of other drugs. This is due to their binding to cytochrome P-450. We tested the in vitro effects of 5 different H2-receptor antagonists cimetidine (C), oxmetidine (O), ranitidine (R), famotidine (F) and nizatidine (N) on arylhydrocarbon-hydroxylase, 7-ethoxycoumarin-O-deethylase and 7-ethoxy-resorufin-O-deethylase activity using liver microsomes from man as well as from untreated, phenobarbital and 3-methylcholanthrene treated rats. In addition their binding to human microsomal cytochrome P-450 was evaluated. The in vivo effects of these antagonists were investigated on the hepatic elimination of diazepam in healthy volunteers. In vitro O was found to be the most effective inhibitor of the enzyme activities studied. C showed a clear inhibitory effect only with rat liver microsomes whereas the remaining drugs were more than 10 times less potent. The binding affinities of these antagonists showed a similar tendency: the Ks-values for O, C and R were 0.2, 0.9 and 5.1 mM, respectively; for F and N no binding up to 4 mM could be observed. However, in man, only C inhibited the hepatic elimination of diazepam by about 45% while R, O, N and F did not affect the pharmacokinetics of diazepam. Thus, it could be concluded from our studies that one cannot extrapolate in vitro data of the inhibitory potency of H2-receptor antagonists in every case to human in vivo drug metabolism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878667     DOI: 10.1016/0006-2952(86)90763-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity.

Authors:  K A Bachmann; T J Sullivan; L Jauregui; J H Reese; K Miller; L Levine
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

2.  Does H2-receptor antagonist alter the renal function of cyclosporine-treated kidney grafts?

Authors:  S Inoue; H Sugimoto; T Nagao; N Akiyama
Journal:  Jpn J Surg       Date:  1990-09

Review 3.  Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A H Price; R N Brogden
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 5.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

Review 6.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 7.  Drug interactions between prescribed and over-the-counter medication.

Authors:  P K Honig; B K Gillespie
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

8.  Reversion by histamine H2-receptor antagonists of plasma membrane alterations in ethanol-induced gastritis.

Authors:  R Hernández-Muñoz; F Montiel-Ruíz
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

Review 9.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.